

# Alexander B Olawaiye

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3752381/publications.pdf>

Version: 2024-02-01

43  
papers

2,485  
citations

430874

18  
h-index

302126

39  
g-index

44  
all docs

44  
docs citations

44  
times ranked

3182  
citing authors

#	ARTICLE	IF	CITATIONS
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
2	Clinical view of gynecologic intraoperative frozen section diagnosis. <i>Gynecology and Obstetrics Clinical Medicine</i> , 2022, 2, 6-8.	0.5	2
3	Molecular profiles of endometrial cancer tumors among Black patients. <i>Gynecologic Oncology</i> , 2022, 166, 108-116.	1.4	11
4	Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5579-5579.	1.6	0
5	Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5503-LBA5503.	1.6	4
6	The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 287-298.	329.8	65
7	Do air gaps with image-guided vaginal cuff brachytherapy impact failure rates in patients with high-intermediate risk FIGO Stage I endometrial cancer?. <i>Brachytherapy</i> , 2021, 20, 512-518.	0.5	3
8	HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5580-5580.	1.6	0
9	Cost-effectiveness analysis of p53 immunohistochemical testing in stage I and II high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18838-e18838.	1.6	0
10	LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5538-5538.	1.6	1
11	FIGO staging for carcinoma of the vulva: 2021 revision. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 43-47.	2.3	42
12	Cancer of the vulva: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 7-18.	2.3	58
13	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz075.	2.9	11
14	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 957-968.	10.7	140
15	Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancer Does it predict treatment response?. <i>Brachytherapy</i> , 2019, 18, 437-444.	0.5	8
16	Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation. <i>Gynecologic Oncology</i> , 2019, 155, 365-373.	1.4	9
17	Revised FIGO staging for carcinoma of the cervix uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 129-135.	2.3	612
18	Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix. <i>Practical Radiation Oncology</i> , 2019, 9, 248-256.	2.1	14

#	ARTICLE	IF	CITATIONS
19	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5518-5518.	1.6	15
20	Chemo First, Then Radiation, and Perhaps Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 290-291.	0.8	0
21	Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual. <i>Gynecologic Oncology</i> , 2018, 150, 7-8.	1.4	17
22	Uterine sarcomas. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 51-58.	2.3	109
23	Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. <i>Oncologist</i> , 2018, 23, 1533-1545.	3.7	21
24	Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2018, 150, 300-305.	1.4	17
25	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.	1.4	18
26	A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5519-5519.	1.6	11
27	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	1.4	21
28	Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience. <i>Gynecologic Oncology</i> , 2017, 147, 315-319.	1.4	9
29	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	1.6	318
30	Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. <i>Brachytherapy</i> , 2015, 14, 9-15.	0.5	20
31	Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. <i>Gynecologic Oncology</i> , 2015, 137, 365-372.	1.4	81
32	A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5613-TPS5613.	1.6	4
33	Comparing outcomes in robotic-assisted and conventional laparoscopic endometrioid endometrial cancer: A study of practice patterns in 42,197 patients over 2 years.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16524-e16524.	1.6	0
34	Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. <i>OncoTargets and Therapy</i> , 2014, 7, 1409.	2.0	20
35	Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. <i>Gynecologic Oncology</i> , 2014, 135, 190-195.	1.4	20
36	Endometrial cancer: A review and current management strategies: Part II. <i>Gynecologic Oncology</i> , 2014, 134, 393-402.	1.4	305

#	ARTICLE	IF	CITATIONS
37	Recurrent breast carcinoma presenting as postmenopausal vaginal bleeding: A case report. <i>Gynecologic Oncology Reports</i> , 2014, 10, 38-40.	0.6	8
38	Endometrial cancer: A review and current management strategies: Part I. <i>Gynecologic Oncology</i> , 2014, 134, 385-392.	1.4	339
39	Vulvar hemangiopericytoma: A case report and literature review. <i>Gynecologic Oncology Case Reports</i> , 2012, 2, 146-149.	0.9	6
40	Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2009, 112, 506-510.	1.4	54
41	Updates on uterine papillary serous carcinoma. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 647-657.	0.4	2
42	Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, 293-298.	1.4	53
43	Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. <i>Gynecologic Oncology</i> , 2007, 106, 628-630.	1.4	27